Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.78 Insider Own23.37% Shs Outstand35.84M Perf Week15.31%
Market Cap583.70M Forward P/E- EPS next Y-5.11 Insider Trans0.00% Shs Float27.68M Perf Month-0.98%
Income-135.31M PEG- EPS next Q-1.04 Inst Own74.50% Short Float9.40% Perf Quarter31.38%
Sales0.00M P/S- EPS this Y-34.48% Inst Trans-2.46% Short Ratio5.74 Perf Half Y48.80%
Book/sh15.10 P/B1.07 EPS next Y-20.55% ROA-19.93% Short Interest2.60M Perf Year13.56%
Cash/sh12.43 P/C1.30 EPS next 5Y- ROE-22.67% 52W Range8.20 - 18.75 Perf YTD47.58%
Dividend Est.- P/FCF- EPS past 5Y-40.62% ROI-24.79% 52W High-13.81% Beta1.40
Dividend TTM- Quick Ratio13.51 Sales past 5Y-23.53% Gross Margin93.02% 52W Low97.07% ATR (14)0.81
Dividend Ex-Date- Current Ratio13.51 EPS Y/Y TTM-1262.29% Oper. Margin0.00% RSI (14)57.65 Volatility4.69% 5.02%
Employees157 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price32.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-144.88% Payout- Rel Volume0.43 Prev Close16.21
Sales Surprise- EPS Surprise-8.91% Sales Q/Q-100.00% EarningsMay 10 BMO Avg Volume453.07K Price16.16
SMA206.63% SMA503.85% SMA20036.53% Trades Volume193,315 Change-0.31%
Date Action Analyst Rating Change Price Target Change
May-05-21Initiated H.C. Wainwright Buy $37
Oct-08-20Initiated Robert W. Baird Outperform $45
Aug-18-20Initiated Wedbush Outperform $45
Aug-18-20Initiated SVB Leerink Outperform $45
Aug-18-20Initiated Piper Sandler Overweight $50
Aug-18-20Initiated JP Morgan Overweight $40
Jul-09-24 12:33PM
Jul-08-24 07:00AM
Jun-18-24 06:33AM
Jun-17-24 09:00AM
May-13-24 08:28AM
01:53PM Loading…
May-10-24 01:53PM
Apr-07-24 04:30PM
Mar-06-24 02:51PM
04:30PM Loading…
Mar-05-24 04:30PM
Mar-01-24 07:00AM
Feb-26-24 06:11AM
Jan-08-24 07:00AM
Jan-03-24 07:00AM
Dec-13-23 09:55AM
Nov-27-23 09:55AM
Nov-21-23 07:00AM
Nov-13-23 09:55AM
Nov-10-23 09:55AM
Nov-07-23 07:00AM
Oct-31-23 03:01AM
Oct-16-23 01:46PM
Oct-11-23 05:55PM
07:00AM Loading…
Sep-06-23 07:00AM
Aug-26-23 11:02AM
Aug-24-23 11:30AM
Aug-23-23 04:10PM
Aug-08-23 07:00AM
Jun-21-23 08:00PM
May-13-23 08:03AM
May-11-23 06:11AM
May-10-23 08:35AM
May-05-23 08:51AM
Apr-26-23 08:00PM
Mar-23-23 01:56PM
Mar-21-23 06:07AM
Mar-17-23 06:18AM
Mar-15-23 08:35AM
Feb-28-23 07:00AM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-07-22 08:07AM
Nov-22-22 07:00AM
Nov-10-22 07:55PM
Nov-04-22 05:46PM
Nov-02-22 10:00AM
Oct-18-22 08:36AM
Aug-12-22 06:16AM
Aug-10-22 05:25PM
Aug-02-22 07:00AM
Jun-30-22 08:41AM
May-16-22 06:27AM
May-12-22 05:45PM
May-11-22 04:09PM
Apr-08-22 01:00PM
Mar-26-22 02:51PM
Mar-23-22 05:55PM
Mar-01-22 07:00AM
Feb-24-22 07:55AM
Feb-10-22 07:00AM
Feb-01-22 09:38AM
Jan-19-22 09:38AM
Jan-10-22 07:00AM
Jan-03-22 04:46PM
Dec-31-21 05:44PM
Dec-29-21 12:19PM
Dec-23-21 12:38PM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-10-21 09:38PM
Dec-09-21 04:01PM
Nov-22-21 10:38AM
Nov-16-21 12:20PM
Nov-10-21 05:45PM
Nov-04-21 11:24AM
Nov-03-21 07:00AM
Oct-18-21 10:26AM
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gall MatthewChief Financial OfficerOct 12 '23Buy8.375,00041,85019,429Oct 12 05:09 PM
Boxer Capital, LLCAug 23 '23Sale16.26350,0005,692,6731,804,058Aug 25 09:28 PM